The use of doxycycline to prevent sexually transmitted infections (STIs) is highly effective in sexually active men who have sex with men and in transgender women, according to final published results from the first major U.S. study on doxyPEP. The newly published results add impressive findings from an open-label extension phase of the study—and they allow us to shine a spotlight on the important work we have ahead to improve awareness and uptake of doxyPEP as a valuable part of routine health care.
Read the full news story at TheBodyPro.
Source : TheBodyPro
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.